Ashton C. Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ashton C. Lai has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Rajeev Samtani
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
7 shared publicationsFrans Beerkens
The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York USA
4 shared publications- Craig M. Crews
Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, USA
3 shared publications Eric Stern
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
3 shared publications- Jason Feinman
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York
3 shared publications - Martin E. Goldman
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
3 shared publications
Latest Publications
- Open Access
- 13 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7644
The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient
Lung transplantation can greatly improve quality of life and extend survival in those with end-stage lung disease. In order to derive the maximal benefit from such a procedure, patients must be carefully selected and be otherwise healthy enough to survive a high-risk surgery and sometimes prolonged immunosuppressive therapy following surgery. Patients therefore must be critically assessed prior to being listed for transplantation with close attention paid towards assessment of cardiovascular health and operative risk. One of the biggest dictators of this is coronary artery disease. In this review article, we discuss the assessment and management of coronary artery disease in the potential lung transplant candidate.
- 13 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7644
Open AccessThe Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient
Lung transplantation can greatly improve quality of life and extend survival in those with end-stage lung disease. In order to derive the maximal benefit from such a procedure, patients must be carefully selected and be otherwise healthy enough to survive a high-risk surgery and sometimes prolonged immunosuppressive therapy following surgery. Patients therefore must be critically assessed prior to being listed for transplantation with close attention paid towards assessment of cardiovascular health and operative risk. One of the biggest dictators of this is coronary artery disease. In this review article, we discuss the assessment and management of coronary artery disease in the potential lung transplant candidate.
- 16 June 2023
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 36 (9) , 967-977
Validation of American Society of Echocardiography Guideline-Recommended Parameters of Right Ventricular Dysfunction Using Artificial Intelligence Compared With Cardiac Magnetic Resonance Imaging
- 16 June 2023
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 36 (9) , 967-977
Validation of American Society of Echocardiography Guideline-Recommended Parameters of Right Ventricular Dysfunction Using Artificial Intelligence Compared With Cardiac Magnetic Resonance Imaging
- Open Access
- 22 November 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 6 (12) , ytac446
A case report of acute heart failure and cardiogenic shock caused by catastrophic antiphospholipid syndrome and lupus myocarditis
Background: Catastrophic antiphospholipid syndrome and lupus myocarditis are two rare life-threatening conditions. Case summary: We present a case of a 47-year-old woman admitted in profound cardiogenic shock due to catastrophic antiphospholipid syndrome and lupus myocarditis requiring advanced heart failure therapies, including early mechanical circulatory support. She improved with steroids, immunoglobulins, mycophenolate, and eculizumab. Discussion: This case highlights the importance of early identification of cardiogenic shock secondary to catastrophic antiphospholipid syndrome and lupus myocarditis, the arrhythmogenic complications of myocarditis, and the subsequent management of the disease progression with mechanical and medical support.
- 22 November 2022
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 6 (12) , ytac446
Open AccessA case report of acute heart failure and cardiogenic shock caused by catastrophic antiphospholipid syndrome and lupus myocarditis
Background: Catastrophic antiphospholipid syndrome and lupus myocarditis are two rare life-threatening conditions. Case summary: We present a case of a 47-year-old woman admitted in profound cardiogenic shock due to catastrophic antiphospholipid syndrome and lupus myocarditis requiring advanced heart failure therapies, including early mechanical circulatory support. She improved with steroids, immunoglobulins, mycophenolate, and eculizumab. Discussion: This case highlights the importance of early identification of cardiogenic shock secondary to catastrophic antiphospholipid syndrome and lupus myocarditis, the arrhythmogenic complications of myocarditis, and the subsequent management of the disease progression with mechanical and medical support.
- 25 May 2022
- Published by Morressier GmbH
Validation of an Artificial Intelligence-based Software for Assessing Right Ventricular Function by Transthoracic Echocardiography
Background: Transthoracic echocardiographic (TTE) assessment of right ventricular (RV) function is challenging since the RV is not fully imaged i |
- 25 May 2022
- Published by Morressier GmbH
Validation of an Artificial Intelligence-based Software for Assessing Right Ventricular Function by Transthoracic Echocardiography
Background: Transthoracic echocardiographic (TTE) assessment of right ventricular (RV) function is challenging since the RV is not fully imaged i |
- 17 February 2022
- Published by Wiley in Echocardiography
- Vol. 39 (3) , 473-482
Assessment and validation of a novel fast fully automated artificial intelligence left ventricular ejection fraction quantification software
Background: Quantification of left ventricular ejection fraction (LVEF) by transthoracic echocardiography (TTE) is operator‐dependent, time‐consuming, and error‐prone. LVivoEF by DIA is a new artificial intelligence (AI) software, which displays the tracking of endocardial borders and rapidly quantifies LVEF. We sought to assess the accuracy of LVivoEF compared to cardiac magnetic resonance imaging (cMRI) as the reference standard and to compare LVivoEF to the standard‐of‐care physician‐measured LVEF (MD‐EF) including studies with ultrasound enhancing agents (UEAs).Methods: In 273 consecutive patients, we compared MD‐EF and AI‐derived LVEF to cMRI. AI‐derived LVEF was obtained from a non‐UEA four‐chamber view without manual correction. Thirty‐one patients were excluded: 25 had interval interventions or incomplete TTE or cMRI studies and six had uninterpretable non‐UEA apical views.Results: In the 242 subjects, the correlation between AI and cMRI was r = .890, similar to MD‐EF and cMRI with r = .891 (p = 0.48). Of the 126 studies performed with UEAs, the correlation of AI using the unenhanced four‐chamber view was r = .89, similar to MD‐EF with r = .90. In the 116 unenhanced studies, AI correlation was r = .87, similar to MD‐EF with r = .84. From Bland‐Altman analysis, LVivoEF underreported the LVEF with a bias of 3.63 ± 7.40% EF points compared to cMRI while MD‐EF to cMRI had a bias of .33 ± 7.52% (p = 0.80).Conclusions: Compared to cMRI, LVivoEF can accurately quantify LVEF from a standard apical four‐chamber view without manual correction. Thus, LVivoEF has the ability to improve and expedite LVEF quantification.
- 17 February 2022
- Published by Wiley in Echocardiography
- Vol. 39 (3) , 473-482
Assessment and validation of a novel fast fully automated artificial intelligence left ventricular ejection fraction quantification software
Background: Quantification of left ventricular ejection fraction (LVEF) by transthoracic echocardiography (TTE) is operator‐dependent, time‐consuming, and error‐prone. LVivoEF by DIA is a new artificial intelligence (AI) software, which displays the tracking of endocardial borders and rapidly quantifies LVEF. We sought to assess the accuracy of LVivoEF compared to cardiac magnetic resonance imaging (cMRI) as the reference standard and to compare LVivoEF to the standard‐of‐care physician‐measured LVEF (MD‐EF) including studies with ultrasound enhancing agents (UEAs).Methods: In 273 consecutive patients, we compared MD‐EF and AI‐derived LVEF to cMRI. AI‐derived LVEF was obtained from a non‐UEA four‐chamber view without manual correction. Thirty‐one patients were excluded: 25 had interval interventions or incomplete TTE or cMRI studies and six had uninterpretable non‐UEA apical views.Results: In the 242 subjects, the correlation between AI and cMRI was r = .890, similar to MD‐EF and cMRI with r = .891 (p = 0.48). Of the 126 studies performed with UEAs, the correlation of AI using the unenhanced four‐chamber view was r = .89, similar to MD‐EF with r = .90. In the 116 unenhanced studies, AI correlation was r = .87, similar to MD‐EF with r = .84. From Bland‐Altman analysis, LVivoEF underreported the LVEF with a bias of 3.63 ± 7.40% EF points compared to cMRI while MD‐EF to cMRI had a bias of .33 ± 7.52% (p = 0.80).Conclusions: Compared to cMRI, LVivoEF can accurately quantify LVEF from a standard apical four‐chamber view without manual correction. Thus, LVivoEF has the ability to improve and expedite LVEF quantification.
- 16 November 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 346, 100-102
Echocardiography in the time of Covid-19: Ultrasound enhancing agents save time and augment diagnostic information
- 16 November 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 346, 100-102
Echocardiography in the time of Covid-19: Ultrasound enhancing agents save time and augment diagnostic information
- Open Access
- 24 September 2021
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 36, 100877
Racial and ethnic differences in severity of coronary calcification among patients undergoing PCI: Results from a single-center multiethnic PCI registry
- 24 September 2021
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 36, 100877
Open AccessRacial and ethnic differences in severity of coronary calcification among patients undergoing PCI: Results from a single-center multiethnic PCI registry